Skip to main content

Advertisement

Table 2 Patient’s characteristics

From: Protective effect of early low-dose hydrocortisone on ventilator-associated pneumonia in the cancer patients: a propensity score analysis

Variables Patients without VAP (n = 135) Patients with VAP (n = 55) P
Male gender, n (%) 87 (64.4) 41 (74.5) 0.23
Age (year), median (IQR) 59.2 (52.2–65.8) 60.4 (50.2–67.1) 0.99
Cancer type    0.39
 Haematological malignancy, n (%) 95 (70.4) 35 (63.6)  
 Solid tumour, n (%) 40 (29.6) 20 (36.4)  
Cancer stage    0.91
 Diagnosis, n (%) 36 (26.7) 15 (27.3)  
 Complete remission, n (%) 29 (21.5) 13 (23.6)  
 Partial remission, n (%) 31 (23) 14 (25.5)  
 Evolutive, n (%) 39 (28.9) 13 (23.6)  
HSCT, n (%) 47 (24.7) 14 (25.4) 0.43
Admission purpose    0.32
 Septic shock, n (%) 59 (43.7) 21 (38.2)  
 Acute respiratory failure, n (%) 51 (37.8) 27 (49.1)  
 Coma, n (%) 14 (10.4) 2 (3.6)  
 Others, n (%) 11 (8.1) 5 (9.1)  
Clinical sepsis upon admission    0.042
 Respiratory, n (%) 79 (58.5) 31 (56.4)  
 Non-respiratory, n (%) 31 (23) 6 (10.9)  
 None, n (%) 25 (18.5) 18 (32.7)  
Characteristics upon admission    
 Neutropenia, n (%) 54 (40) 18 (32.7) 0.41
 Antibiotherapy, n (%) 104 (77) 43 (78.2) 1
 Corticosteroids (curative), n (%) 32 (23.7) 19 (34.5) 0.15
SOFA score (day of intubation), median (IQR) 11 (8–14) 11 (8–13) 0.28
Characteristics at the first 48 h of MV    
 Vasopressors, n (%) 99 (73.3) 44 (80) 0.36
 Renal replacement therapy, n (%) 28 (20.7) 9 (16.4) 0.55
 Substitutive hydrocortisone, n (%) 96 (71.1) 26 (47.3) 0.003
 G-CSF, n (%) 20 (14.8) 9 (16.4) 0.82
 Enteral nutrition, n (%) 40 (29.6) 21 (38.2) 0.3
 Antibiotherapy    0.09
  Adapted, n (%) 41 (30.4) 11 (20)  
  Empirical, n (%) 89 (65.9) 38 (69)  
  None, n (%) 5 (3.7) 6 (10.7)  
  1. HSCT haematopoietic stem cell transplantation, G-CSF granulocyte colony-stimulating factors, MV mechanical ventilation, IQR interquartile range